A zebrafish model of CLN2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation.

Abstract

Tripeptidyl peptidase 1 (TPP1) deficiency causes CLN2 disease, late infantile (or classic late infantile neuronal ceroid lipofuscinosis), a paediatric neurodegenerative disease of autosomal recessive inheritance. Patients suffer from blindness, ataxia, epilepsy and cognitive defects, with MRI indicating widespread brain atrophy, and profound neuron loss is evident within the retina and brain. Currently there are no effective therapies for this disease, which causes premature death in adolescence. Zebrafish have been successfully used to model a range of neurological and behavioural abnormalities. The aim of this study was to characterize the pathological and functional consequences of Tpp1 deficiency in zebrafish and to correlate these with human CLN2 disease, thereby providing a platform for drug discovery. Our data show that homozygous tpp1(sa0011) mutant (tpp1(sa0011)(-/-)) zebrafish display a severe, progressive, early onset neurodegenerative phenotype, characterized by a significantly small retina, a small head and curved body. The mutant zebrafish have significantly reduced median survival with death occurring 5 days post-fertilization. As in human patients with CLN2 disease, mutant zebrafish display storage of subunit c of mitochondrial ATP-synthase, hypertrophic lysosomes as well as localized apoptotic cell death in the retina, optic tectum and cerebellum. Further neuropathological phenotypes of these mutants provide novel insights into mechanisms of pathogenesis in CLN2 disease. Secondary neurogenesis in the retina, optic tectum and cerebellum is impaired and axon tracts within the spinal cord, optic nerve and the posterior commissure are disorganized, with the optic nerve failing to reach its target. This severe neurodegenerative phenotype eventually results in functional motor impairment, but this is preceded by a phase of hyperactivity that is consistent with seizures. Importantly, both of these locomotion phenotypes can be assayed in an automated manner suitable for high-throughput studies. Our study provides proof-of-principle that tpp1(sa0011)(-/-) mutants can utilize the advantages of zebrafish for understanding pathogenesis and drug discovery in CLN2 disease and other epilepsies.

• Authors: Fahad Mahmood, Sonia Fu, Jennifer Cooke, Stephen W Wilson, Jonathan D Cooper, Claire Russell
• Journal: Brain : a journal of neurology (Brain) Vol. 136 Issue Pt 5 Pg. 1488-507 (May 2013) ISSN: 1460-2156 [Electronic] England
• PMID: 23587805 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Growth Inhibitors
• Tripeptidyl-Peptidase 1
• Serine Proteases
• Aminopeptidases
• Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
• TPP1 protein, human

Topics

• Aminopeptidases (deficiency, genetics, physiology)
• Animals
• Animals, Genetically Modified
• Cell Proliferation
• Dipeptidyl-Peptidases and Tripeptidyl-Peptidases (deficiency, genetics, physiology)
• Disease Models, Animal
• Disease Progression
• Growth Inhibitors (deficiency, genetics, physiology)
• Humans
• Motor Activity (physiology)
• Neurodegenerative Diseases (enzymology, genetics, pathology)
• Neuronal Ceroid-Lipofuscinoses (enzymology, genetics, pathology)
• Serine Proteases (deficiency, genetics, physiology)
• Tripeptidyl-Peptidase 1
• Zebrafish